Camilla Sandberg
Chief Executive Officer bei MIRIS HOLDING AB
Profil
Camilla Myhre Sandberg is currently the Chief Executive Officer at Miris Holding AB since 2016.
She is also an Independent Director at Monivent AB and NextCell Pharma AB.
Previously, she worked as the Vice President-Sales & Marketing at BioLamina AB.
Ms. Sandberg completed her undergraduate degree in 1996 and MBA in 1998 from the University of Oslo.
Aktive Positionen von Camilla Sandberg
Unternehmen | Position | Beginn |
---|---|---|
MIRIS HOLDING AB | Chief Executive Officer | 04.10.2016 |
NEXTCELL PHARMA AB | Director/Board Member | 01.01.2017 |
MONIVENT AB | Director/Board Member | - |
Ehemalige bekannte Positionen von Camilla Sandberg
Unternehmen | Position | Ende |
---|---|---|
BioLamina AB
BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden. | Sales & Marketing | - |
Ausbildung von Camilla Sandberg
University of Oslo | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
MIRIS HOLDING AB | Electronic Technology |
MONIVENT AB | Health Technology |
NEXTCELL PHARMA AB | Health Technology |
Private Unternehmen | 1 |
---|---|
BioLamina AB
BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden. | Health Technology |